Retinopathy of Prematurity (ROP) is a potentially blinding eye disease that affects preterm babies with very low birth weight. Each year in the US, 28,000 babies are at risk for developing ROP, with more than 500 babies becoming blind from this disease.
Proper screening and early treatment of ROP is cost-effective and can greatly reduce vision los due to ROP, but it is not readily available at many hospitals.
At RetiVue LLC, we are designing the RetiVue WF, an affordable, portable camera that can accurately detect ROP. WE believe that the RetiVue WF will for the first time enable widespread telemedicine screening programs for this disease throughout the US and abroad, and thereby greatly reduce the risk and cost of unnecessary blindness in these infants.
Please see our About Us: Our Motivation page for more information on the importance of eye disease screening.
To read about the development of our patent-pending RetiVue WF imaging platform, please visit our News page.